Semarion Raises GBP£2.14M in Seed Funding

Semarion, a Cambridge, UK-based company combining materials engineering and cell biology to tackle unmet drug screening needs, has raised GBP£2.14M in Seed funding. The round was led by Parkwalk Advisors, with participation from University of Cambridge Seed Funds, and Martlet Capital. Semarion intends to use the funds to support the commercial development of its SemaCyte® cell assaying platform and further expansion of the team, as they recruit scientists and engineers, and establish additional research partnerships with biopharma partners for bespoke solutions to cell screening challenges.

Semarion Secures GBP£2.14M Seed Funding to Advance Drug Screening Technology

Semarion is a Cambridge, UK-based company combining materials engineering and cell biology to tackle unmet drug screening needs. Semarion has developed SemaCyte®, a novel class of cell carrier materials, created using microchip fabrication technologies, nanomagnetism, and smart materials. These assaying microcarriers are flat and function as ultra-miniaturized, magnetically steerable wells which carry small colonies of adherent cells into suspension to improve cell-based experiments. They enable the controlled movement of cell types which need to stick to a surface, namely those typically used for in vitro drug screening work.

Semarion is a Cambridge, UK-based company combining materials engineering and cell biology to tackle unmet drug screening needs.

3 years ago

Semarion Secures GBP£2.14M Seed Funding to Advance Drug Screening Technology

ProblemBiotechnology

Solution

Covered on